ABBVIE
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 11
- Registration Number
- NCT01969695
- Locations
- 🇺🇸
University of Arizona Arthritis Center /ID# 101359, Tucson, Arizona, United States
🇺🇸Dartmouth-Hitchcock Med Ctr /ID# 92596, Lebanon, New Hampshire, United States
🇺🇸Hackensack Univ Med Ctr /ID# 101417, Hackensack, New Jersey, United States
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT01969682
- Locations
- 🇺🇸
Site Reference ID/Investigator# 101416, Hackensack, New Jersey, United States
Evaluation of Diet and Exercise in Prostate Cancer Patients
- Conditions
- Prostate Cancer
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1331
- Registration Number
- NCT01960881
- Locations
- 🇨🇦
Exdeo Clinical Research Inc /ID# 116040, Abbotsford, British Columbia, Canada
🇨🇦Dr. J. Paul Whelan, Inc. /ID# 120415, Victoria, British Columbia, Canada
🇨🇦QE II Health Sciences Centre /ID# 118941, Halifax, Nova Scotia, Canada
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
- Conditions
- Behcet's Disease
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 473
- Registration Number
- NCT01960790
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Drug: Levodopa-carbidopa intestinal gelDevice: CADD-Legacy® 1400 ambulatory infusion pumpDevice: PEG tubeDevice: J-tube
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 31
- Registration Number
- NCT01960842
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: ABT-494Drug: Placebo
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 276
- Registration Number
- NCT01960855
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Biological: Adalimumab
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT01958827
Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
- Conditions
- Parkinson's Disease
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 15
- Registration Number
- NCT01956032
Special Investigation in Patients With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1621
- Registration Number
- NCT01947816
A Study of ABT-165 in Subjects With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 101
- Registration Number
- NCT01946074
- Locations
- 🇺🇸
HonorHealth Research Institute - Pima /ID# 105677, Scottsdale, Arizona, United States
🇺🇸University of California, Los Angeles /ID# 141389, Los Angeles, California, United States
🇺🇸Scottsdale Healthcare /ID# 105678, Scottsdale, Arizona, United States